Trial Profile
A Phase 2, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 23 Jan 2024
Price :
$35
*
At a glance
- Drugs Pemigatinib (Primary)
- Indications Lymphoid leukaemia; Lymphoma; Myeloid leukaemia
- Focus Registrational; Therapeutic Use
- Acronyms FIGHT-203
- Sponsors Incyte Corporation
- 12 Dec 2023 Results(As of June 30, 2021, n=39) presented at the 65th American Society of Hematology Annual Meeting and Exposition.
- 24 Sep 2023 This trial has been completed in Belgium , according to European Clinical Trials Database record.
- 30 Jun 2023 Planned End Date changed from 12 Jun 2023 to 31 Jul 2024.